Group 1: Company Growth and Strategy - The company focuses on enhancing core competitiveness by tracking technological advancements and increasing market expansion efforts [2] - Plans to improve production efficiency and profitability through optimized manufacturing processes and capacity utilization [2] - The CRO industry is experiencing rapid growth due to rising R&D costs and efficiency demands, with China becoming a key market for overseas R&D orders [2] Group 2: AI Integration and Development - The company has integrated AI technology into drug development, achieving significant progress in drug design and molecular screening [3] - AI drug development is a core innovation direction, with ongoing investments to overcome challenges such as data quality and model generalization [3] - The ADMET prediction model is based on proprietary technology, utilizing both public and proprietary data to enhance accuracy [4] Group 3: Financial Performance and Shareholder Value - The company emphasizes that the financial performance should be referenced from the disclosed periodic reports [5] - A major shareholder's reduction in holdings is driven by personal financial needs, with no expected impact on the company's operations [5] - The company is implementing share buybacks and increasing dividend frequency to stabilize market expectations and enhance shareholder returns [5]
泓博医药(301230) - 301230泓博医药投资者关系管理信息20250516